Sodium–glucose cotransporter 2 inhibitors (SGLT2i), which originally emerged as antihyperglycemic agents, block glucose resorption in the proximal tubule of the kidneys, and promote glucosuria, reducing blood glucose levels in an insulin-independent manner in Type 2 diabetes mellitus (T2DM) patients [1]. Here, INS is linked to type 2 diabetes mellitus.